John T. Delacourt

Vice President, Legal Affairs and Global Operations, Plasma Protein Therapeutics Association

John Delacourt is Vice President, Legal Affairs & Global Operations for the Plasma Protein Therapeutics Association (PPTA).  PPTA is a global trade association that represents manufacturers of plasma-derived and recombinant biological therapies, as well as the world's leading source plasma collectors.  PPTA's member companies include Biotest, BPL, CSL Behring, Grifols, Kedrion, and Shire. As PPTA’s chief legal officer, Mr. Delacourt is responsible for advancing consensus industry positions before U.S. (FTC, FDA, USTR) and European (European Commission, EMA, NCAs) regulatory authorities, including on such issues as antitrust compliance, U.S. and European health policy, shortage preparedness, international trade, and ADA compliance.  Prior to joining PPTA, he was Special Counsel with Kelley Drye & Warren LLP.  Prior to that, he served as Chief Antitrust Counsel of the Federal Trade Commission’s Office of Policy Planning.  He is a graduate of Harvard Law School (cum laude) and Georgetown University (summa cum laude).

The Federalist Society takes no position on particular legal or public policy issues. The people listed as Experts have spoken or otherwise participated in Federalist Society events, publications, or multimedia presentations. A person's appearance on this list does not imply any other endorsement or relationship between the person and the Federalist Society. All expressions of opinion by an expert are those of the expert.

Publications and Multimedia
The European Commission’s Google Decision: Searching for Answers - Podcast
Corporations, Securities & Antitrust and Telecommunications & Electronic Media Practice Group Podcast
September 21, 2017
Assessing Recent FTC Merger Litigation: One Win, One Loss, and One Tie - Event Audio/Video
Corporations, Securities, and Antitrust Practice Group
June 05, 2008
Class Action Fairness Act: Two Years Later - Event Audio
Litigation Practice Group and Corporations, Securities & Antitrust Practice Group
February 14, 2007